SPOTLIGHT: ReNeuron looks to resolve FDA issues

ReNeuron is hoping that a meeting Feb. 14 with FDA officials will resolve the agency's concerns over its ReN001 stem cell therapy, which prompted the agency to put a clinical hold on the therapy. Release

Suggested Articles

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.

Durect’s share price fell 12% after half of the panel of painkiller experts recommended against approving Posimir.

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite.